Innoviva Inc (INVA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.35B
Last updated: Nov 17, 2026 at 11:06 AM ET
Innoviva Inc (INVA) P/E Ratio & Valuation History
Innoviva (INVA) trades at 5.3x trailing earnings and 3.0x sales. Its P/E of 5.3x is below its 5-year median of 10.7x. Its forward P/E is 8.5x.
Current Multiples
Its forward P/E is above its trailing P/E, which implies earnings per share about 37.6% lower over the next year. PEG is left out because the growth rate behind it, P/E divided by PEG, is under 2% a year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 5.3x |
| Forward P/E | 8.5x |
| Price to sales | 3.0x |
| Price to book | 1.2x |
| EV/EBITDA | 4.7x |
| Price to FCF | 7.3x |
| EV/FCF | 5.5x |
| PEG | N/A |
| FCF yield | 13.7% |
Historical Medians
Against its 10-year medians, its P/E is 41.8% below 9.1x and its P/S is 21.1% below 3.8x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 5.3x | 10.7x | 9.1x |
| P/S | 3.0x | 3.4x | 3.8x |
| P/B | 1.2x | 1.6x | N/A |
Valuation History
Over the 10 year ends shown, its P/E ranged from 6.2x in 2021 to 59.8x in 2024.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $19.99 | 6.6x | 3.4x | 1.5x |
| 2024 | $17.35 | 59.8x | 3.2x | 2.1x |
| 2023 | $16.04 | 11.6x | 3.6x | 2.0x |
| 2022 | $13.25 | 21.4x | 2.8x | 1.6x |
| 2021 | $17.25 | 6.2x | 3.7x | 3.4x |
| 2020 | $12.39 | 7.0x | 3.8x | 2.6x |
| 2019 | $14.16 | 9.9x | 5.7x | 5.1x |
| 2018 | $17.45 | 9.7x | 7.0x | 12.9x |
| 2017 | $14.19 | 11.7x | 7.2x | N/A |
| 2016 | $10.70 | 20.6x | 9.1x | N/A |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About INVA
What is INVA's forward P/E ratio?
Innoviva has a forward P/E ratio of 8.5x.
Is INVA stock overvalued?
GNG's valuation label for INVA is Undervalued.
What is INVA's price to sales ratio?
Innoviva has a price to sales ratio of 3.0x.
What is Innoviva's average P/E ratio over 5 years?
Innoviva's median P/E over the last 5 years is 10.7x, from 51 month-end values through Oct 2026.
INVA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors